Back to today’s briefing

Story perspectives

FDA Warns Novo Nordisk Over Unreported Patient Deaths

3/15/2026

40 6 Full Breakdown

Summary

Story summary

The U.S. Food and Drug Administration (FDA) issued a warning letter to Novo Nordisk for failing to report serious adverse events related to GLP-1 medications, including semaglutide.
The FDA cites systemic failures in safety reporting, noting three patient deaths and an unreported stroke.
Novo Nordisk must outline corrective actions within 15 business days and the FDA notes that responses have not prevented future violations.

History

Historical Context

The FDA established the REMS program in 2004 to improve drug safety monitoring following the Vioxx scandal, which caused over 27,000 heart attacks. Recent issues with Novo Nordisk's reporting of serious adverse events related to GLP-1 medications, including semaglutide, highlight ongoing concerns about pharmaceutical accountability and the need for stricter compliance to protect patient safety.

1 of 2

Story summary

The U.S. Food and Drug Administration (FDA) issued a warning letter to Novo Nordisk for failing to report serious adverse events related to GLP-1 medications, including semaglutide.
The FDA cites systemic failures in safety reporting, noting three patient deaths and an unreported stroke.
Novo Nordisk must outline corrective actions within 15 business days and the FDA notes that responses have not prevented future violations.

1 / 2